Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. On average, analysts expect Marinus Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Marinus Pharmaceuticals, Inc. (NASDAQ MRNS) opened at 5.10 on Wednesday. The stock’s market cap is $132.98 million. Marinus Pharmaceuticals, Inc. has a 12-month low of $0.82 and a 12-month high of $8.22. The company has a 50-day moving average of $5.07 and a 200 day moving average of $2.56.

MRNS has been the subject of several research reports. ValuEngine lowered Marinus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, July 7th. JMP Securities reiterated an “outperform” rating and set a $11.00 price target (up from $5.00) on shares of Marinus Pharmaceuticals in a report on Tuesday, September 12th.

TRADEMARK VIOLATION WARNING: “Marinus Pharmaceuticals, Inc. (MRNS) Scheduled to Post Quarterly Earnings on Wednesday” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/25/marinus-pharmaceuticals-inc-mrns-scheduled-to-post-quarterly-earnings-on-wednesday.html.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.